Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma

PLoS ONE

Volumn 12, Issue 4, 2017, Pages

  Takamochi, Kazuya ^a   Mogushi, Kaoru ^a   Kawaji, Hideya ^b   Imashimizu, Kota ^a   Fukui, Mariko ^a   Oh, Shiaki ^a   Itoh, Masayoshi ^b   Hayashizaki, Yoshihide ^b   Ko, Weijey ^c   Akeboshi, Masao ^c   Suzuki, Kenji ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RIKEN   (Japan)

^c Diagnostic Imaging Center Kameda Kyobashi Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; MESSENGER RNA; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANLN GENE; ARTICLE; CDC25A GENE; CIT GENE; CONTROLLED STUDY; EGFR GENE; FEMALE; G6PD GENE; GAPDH GENE; GENE EXPRESSION; GENE MUTATION; GLUCOSE METABOLISM; GPI GENE; HUMAN; KPNA2 GENE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL; PKM2 GENE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PREDICTION; PREDICTIVE VALUE; PTTG1 GENE; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; TRANSCRIPTION INITIATION; ADENOCARCINOMA; DIAGNOSTIC IMAGING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION; POSITRON EMISSION TOMOGRAPHY; TRANSPORT AT THE CELLULAR LEVEL;

ADENOCARCINOMA; AGED; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS P21(RAS); RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROC CURVE; TRANSCRIPTION INITIATION, GENETIC;

EID: 85018506251     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0175622     Document Type: Article

References (37)

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. Epub 2010/ 06/25. https://doi.org/10.1056/NEJMoa0909530 PMID: 20573926
2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11(2):121-8. Epub 2009/12/22. https://doi.org/10.1016/S1470-2045(09)70364-X PMID: 20022809
3. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25):5900-9. https://doi.org/10.1200/JCO.2005.02.857 PMID: 16043828
4. Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol. 2003; 45(1):49-59. PMID: 12499064
5. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2000; 41(1):85-92. Epub 2000/01/27.
6. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6(10):3837-44. Epub 2000/10/29.
7. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The oncologist. 2002; 7 Suppl 4:2-8. Epub 2002/08/31.
8. Shiraki T, Kondo S, Katayama S, Waki K, Kasukawa T, Kawaji H, et al. Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(26):15776- 81. Epub 2003/12/10. PubMed Central PMCID: PMCPmc307644. https://doi.org/10.1073/pnas.2136655100 PMID: 14663149
9. Nonaka D. A study of DeltaNp63 expression in lung non-small cell carcinomas. The American journal of surgical pathology. 2012; 36(6):895-9. Epub 2012/03/01. https://doi.org/10.1097/PAS.0b013e3182498f2b PMID: 22367298
10. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, et al. An atlas of active enhancers across human cell types and tissues. Nature. 2014; 507(7493):455-61. Epub 2014/03/29.https://doi.org/10.1038/nature12787 PMID: 24670763
11. Forrest AR, Kawaji H, Rehli M, Baillie JK, de Hoon MJ, Lassmann T, et al. A promoter-level mammalian expression atlas. Nature. 2014; 507(7493):462-70. Epub 2014/03/29. https://doi.org/10.1038/ nature13182 PMID: 24670764
12. Arner E, Daub CO, Vitting-Seerup K, Andersson R, Lilje B, Drablos F, et al. Gene regulation. Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (New York, NY). 2015; 347(6225):1010-4. Epub 2015/02/14.
13. Takamochi K, Ohmiya H, Itoh M, Mogushi K, Saito T, Hara K, et al. Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung. BMC Cancer. 2016; 16(1):760. https://doi.org/10.1186/s12885-016-2792-1 PMID: 27681076
14. Hattori A, Suzuki K, Matsunaga T, Fukui M, Tsushima Y, Takamochi K, et al. Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c- Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan. Interactive cardiovascular and thoracic surgery. 2014; 18(3):329-34. Epub 2013/12/20. PubMed Central PMCID: PMCPMC3930213. https://doi.org/10.1093/icvts/ivt500 PMID: 24351509
15. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005; 65 (16):7276-82. https://doi.org/10.1158/0008-5472.CAN-05-0331 PMID: 16105816
16. Thiede C, Bayerdorffer E, Blasczyk R, Wittig B, Neubauer A. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res. 1996; 24 (5):983-4. Epub 1996/03/01. PMID: 8600471
17. Murata M, Nishiyori-Sueki H, Kojima-Ishiyama M, Carninci P, Hayashizaki Y, Itoh M. Detecting expressed genes using CAGE. Methods Mol Biol. 2014; 1164:67-85. Epub 2014/06/15. https://doi.org/ 10.1007/978-1-4939-0805-9-7 PMID: 24927836
18. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010; 11 (10):R106. Epub 2010/10/29. PubMed Central PMCID: PMCPMC3218662. https://doi.org/10.1186/gb- 2010-11-10-r106 PMID: 20979621
19. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (Oxford, England). 2010; 26(1):139-40. Epub 2009/11/17. PubMed Central PMCID: PMCPmc2796818.
20. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80. Epub 2004/10/06. PubMed Central PMCID: PMCPmc545600. https://doi.org/10.1186/gb-2004-5-10-r80 PMID: 15461798
21. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols. 2009; 4(1):44-57. Epub 2009/01/10. https://doi.org/ 10.1038/nprot.2008.211 PMID: 19131956
22. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research. 2009; 37(1):1-13. Epub 2008/ 11/27. PubMed Central PMCID: PMCPmc2615629. https://doi.org/10.1093/nar/gkn923 PMID: 19033363
23. Huang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Medical oncology (Northwood, London, England). 2010; 27(1):9-15. Epub 2009/01/09.
24. Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. The oncologist. 2011; 16(3):319-26. Epub 2011/02/23. https://doi.org/10. 1634/theoncologist.2010-0300 PMID: 21339258
25. Na II, Byun BH, Kim KM, Cheon GJ, Choe du H, Koh JS, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung cancer (Amsterdam, Netherlands). 2010; 67(1):76-80. Epub 2009/04/18.
26. Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, et al. Value of (1)(8)F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. European journal of nuclear medicine and molecular imaging. 2014; 41(10):1889-97. Epub 2014/05/24. https://doi.org/10.1007/s00259-014-2802-y PMID: 24852187
27. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006; 11(3):190-8. Epub 2006/07/20. https://doi.org/10.1007/s10147-006-0583-4 PMID: 16850125
28. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5):339-46. Epub 2005/03/03. https://doi.org/10.1093/jnci/dji055 PMID: 15741570
29. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006; 1(3):231-9. Epub 2007/ 04/06. PMID: 17409862
30. Higashi K, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Matsunari I, et al. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2005; 46(2):267-73. Epub 2005/02/08.
31. Mueckler M, Caruso C, Baldwin SA, Panico M, Blench I, Morris HR, et al. Sequence and structure of a human glucose transporter. Science (New York, NY). 1985; 229(4717):941-5. Epub 1985/09/06.
32. Suganuma N, Segade F, Matsuzu K, Bowden DW. Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. BJU international. 2007; 99(5):1143-9. Epub 2007/04/18. https://doi.org/10.1111/j.1464-410X.2007.06765.x PMID: 17437443
33. Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with [18 F]FDG uptake in non-small cell lung cancer. European journal of nuclear medicine. 2000; 27(12):1778-85. Epub 2001/02/24.
34. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia (New York, NY). 2005; 7(4):369-79. Epub 2005/06/22. PubMed Central PMCID: PMC1501150.
35. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. European journal of cancer (Oxford, England: 1990). 2007; 43(9):1392-8. Epub 2007/05/22.
36. Sasaki H, Shitara M, Yokota K, Hikosaka Y, Moriyama S, Yano M, et al. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Molecular medicine reports. 2012; 5(3):599-602. Epub 2011/12/28. https://doi.org/10.3892/mmr.2011.736 PMID: 22200795
37. Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2014; 83(2):197-204. Epub 2013/12/25.